Ribociclib 600mg trials for Breast cancer

All Ribociclib 600mg trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Ribociclib 600mg for Breast cancer

• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 37 locations
• Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
  NCT07164976 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
  NCT06377852 · Phase: Phase 3 · Ages: 60 Years and older · Sex: All (male and female) · 73 locations

Common questions

How many trials study Ribociclib 600mg for Breast cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.